Capability

Cell and gene therapy manufacturing in Singapore

GMP production of living therapeutics — autologous and allogeneic cell therapies, viral vectors and plasmid DNA. Buyers select on modality, platform and scale, stage from clinical-trial material to commercial supply, and captive-versus-shared-versus-CDMO contracting model under HSA's cell, tissue and gene therapy product regime.

Cell and gene therapy (CGT) manufacturing is the frontier tier of Singapore's biomedical build-out — the GMP production of living therapeutics: autologous and allogeneic cell therapies, viral vectors, plasmid DNA and other advanced-therapy medicinal products. It is smaller and younger than the antibody and small-molecule pillars, but it is where the state is deliberately investing to move up the value chain. The Advanced Cell Therapy and Research Institute, Singapore (Actris) opened in 2023 as a roughly 2,000 m² national GMP facility on the Singapore General Hospital campus with 14 clean suites, backed by a Ministry of Health precision-medicine task force; the EDB frames the opportunity against a global cell-therapy market projected to grow from about US$5.46 billion to US$15.89 billion by 2028, with roughly 100 Singapore patients a year needing CGT. The regulatory frame is the Health Sciences Authority's cell-tissue-and-gene-therapy-product regime under PIC/S GMP.

The buyer's read on a CGT plant is specific: modality (autologous versus allogeneic cell therapy, viral-vector, plasmid DNA, mRNA-adjacent); platform and scale (single-use closed systems, proprietary bioreactors, vector titre); stage (clinical trial material versus commercial supply); and captive-versus-shared-versus-CDMO model, which matters more here than elsewhere because much of Singapore's CGT capacity is national or academic shared infrastructure rather than commercial merchant capacity. The field is thin but real: Lonza's allogeneic cell-therapy centre of excellence at its Tuas campus is the largest commercial anchor; Esco Aster is the notable homegrown CDMO spanning viral vector, cell therapy (on its Tide Motion platform) and plasmid DNA; and Actris provides shared GMP suites for hospitals, research institutions and startups. The honest caveat is that this is an emerging set — several players are shared or academic facilities, and the merchant-CDMO tier is still forming — so the record should verify each firm's contracting model rather than assume commercial availability.

Also known as: CGT manufacturing · advanced therapy manufacturing · cell therapy manufacturing · gene therapy manufacturing · viral vector manufacturing · ATMP manufacturing

Capability specifications

Modalities: Autologous and allogeneic cell therapy, viral vector, plasmid DNA
Platform: Single-use closed systems, proprietary bioreactors, vector production
Stage: Clinical-trial material and commercial supply
Model: Captive, national/shared GMP, or commercial CDMO
Regulatory: HSA cell, tissue and gene therapy product (CTGTP) regime; PIC/S GMP

Companies with this capability in Singapore

Lonza Biologics Tuas
A large mammalian cell-culture CDMO campus at Tuas producing monoclonal antibodies and recombinant and fusion proteins across 20,000-litre stainless-steel and 2,000-litre single-use suites, with cell-line construction through commercial process validation, purification, viral clearance and fill, plus an allogeneic cell-therapy centre of excellence and a strong regulatory-inspection record.
Website (opens Lonza Biologics Tuas in a new tab)
Esco Aster
A homegrown Singapore CDMO at Ayer Rajah Crescent offering biologics, viral-vector production, cell-therapy manufacturing on its proprietary Tide Motion bioreactor platform, plasmid-DNA manufacturing and small-batch aseptic fill-finish — positioned as Southeast Asia's first small-batch aseptic fill-and-finish service — with an A*STAR bioprocessing partnership.
Website (opens Esco Aster in a new tab)
Actris (Advanced Cell Therapy and Research Institute, Singapore)
A roughly 2,000 m2 GMP cell-therapy facility on the Singapore General Hospital campus with 14 clean suites, 4 translational labs and a QC lab, enabling hospitals, research institutions and biotech startups to carry out cell selection, genetic modification and manufacture of cell therapies locally — a national shared-GMP facility.
Website (opens Actris (Advanced Cell Therapy and Research Institute, Singapore) in a new tab)

ENQUIRE

Not sure which supplier?

Tell the Singapore Industry Index what you need — this enquiry is tagged to Cell and gene therapy manufacturing — and we'll point you to the companies on the record that do it. To reach one company directly, enquire from its profile above.